References
1. Marr K, Kauffman C, Thomer A. Epidemiology and clinical manifestations of invasive aspergillosis. UpToDate Waltham (MA).2015.
2. Paulussen C, Hallsworth JE, Alvarez-Perez S, et al. Ecology of aspergillosis: insights into the pathogenic potency of Aspergillus fumigatus and some other. 2016.
3. Segal BH. Aspergillosis. New England Journal of Medicine.2009;360(18):1870-1884.
4. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis.Drugs. 2007;67(11):1567-1601.
5. Allo MD, Miller J, Townsend T, Tan C. Primary cutaneous aspergillosis associated with Hickman intravenous catheters. New England Journal of Medicine. 1987;317(18):1105-1108.
6. Van Burik J-AH, Colven R, Spach DH. Cutaneous aspergillosis.Journal of clinical microbiology. 1998;36(11):3115-3121.
7. Dreizen S, Bodey GP, McCredie KB, Keating MJ. Orofacial aspergillosis in acute leukemia. Oral surgery, oral medicine, oral pathology.1985;59(5):499-504.
8. Findlay G, Roux H, Simson I. SKIN MANIFESTATIONS IN DISSEMINATED ASPERGI LLOSIS. British Journal of Dermatology. 1971;85:94-97.
9. Kudoh A, Okawa Y, Shibata N. Significant structural change in both O-and N-linked carbohydrate moieties of the antigenic galactomannan from Aspergillus fumigatus grown under different culture conditions.Glycobiology. 2015;25(1):74-87.
10. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis disease spectrum, treatment practices, and outcomes. Medicine.2000;79(4):250-260.
11. Ho C-H, Chen Y-C, Chu C-C, Wang J-J, Liao K-M. Postoperative complications after coronary artery bypass grafting in patients with chronic obstructive pulmonary disease. Medicine. 2016;95(8).
12. Jørgensen KJ, Gøtzsche PC, Johansen HK. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database of Systematic Reviews. 2006(1).
13. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clinical infectious diseases.2008;46(3):327-360.